On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sanofi Japan Highlights Beyfortus Track Record with NIP Inclusion in Sight
November 11, 2026
-
BUSINESS Vital KSK’s Medleap Pivots to In-House Drug Filings, Eyes 2029 Launch
November 10, 2026
-
REGULATORY Kyowa Kirin’s Libmeldy Gene Therapy Now in Line for Japan Approval
November 10, 2026
-
REGULATORY Keytruda SC Tops New NHI Listing Round with 75 Billion Yen Sales Outlook
November 9, 2026
-
REGULATORY Japan Set to Prioritize Pharma in Growth Strategy Action Plan
November 9, 2026
-
REGULATORY Kisunla Price Cut Set at 3.93% under Japan’s CEA Scheme
November 6, 2026
-
REGULATORY Japan Nudged to Probe Wide Gaps in Biosimilar Uptake
November 6, 2026
-
BUSINESS Fuji Pharma Recalls Eylea Biosimilar Lots over Faulty Finger Grips
November 6, 2026
-
REGULATORY JPMA Urges Foreign Price Rule Overhaul to Address US MFN Policy: LDP Hearing
November 5, 2026
-
REGULATORY MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
-
ACADEMIA Tavneos Patients Shift to Other Therapies as Japan Weighs Revocation: Investigator
November 4, 2026
-
REGULATORY Japan Panel to Review Kyowa Kirin’s Libmeldy for Approval on Nov. 9
November 4, 2026
-
COMMENTARY Deeper CEA Price Cuts Demand More Than a “Certain Degree of Validity”
November 2, 2026
-
REGULATORY Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
-
BUSINESS Takeda Returns to Core Profit Growth, CEO Confident in Trajectory
October 30, 2026
-
REGULATORY PMDA Halts Medical Device Application Platform after Unauthorized Access
October 30, 2026
-
REGULATORY Chuikyo Reps Back More Pharma Access to CEA Deliberations, Urge Neutrality
October 29, 2026
-
REGULATORY FY2027 Revision: HCPs Press for Action on Drug Shortages, Negative Margins
October 29, 2026
-
REGULATORY Zolgensma Cost-Effectiveness Analysis to Resume after Five-Year Halt
October 29, 2026
-
BUSINESS Lundbeck Japan Boosts Workforce 20% as It Revs Up Domestic Operations
October 28, 2026
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…